Business Context and Reporting Period
Company: Techne Corporation (BIO-TECHNE Corp)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and nine months ended March 31, 1998
Business Overview: The Company operates through two subsidiaries: Research & Diagnostic Systems, Inc. (R&D Systems) in the U.S. and R&D Systems Europe Ltd. R&D Systems comprises Biotechnology (cytokines, antibodies, assay kits) and Hematology (controls and calibrators) divisions. In late 1997 and early 1998, the Company invested in ChemoCentryx, Inc. (CCX), consolidating its financials due to significant ownership and control.
Key Financial Metrics
| Metric | Quarter Ended 3/31/98 | Nine Months Ended 3/31/98 | Nine Months Ended 3/31/97 |
|---|---|---|---|
| Sales | $17,698,472 | $48,708,472 | $44,688,099 |
| Gross Margin | $12,207,506 (69.0%) | $33,785,744 (69.4%) | $30,358,503 (67.9%) |
| Net Earnings | $4,022,658 | $10,413,024 | $7,404,662 |
| Diluted EPS | $0.20 | $0.53 | $0.38 |
| Cash & Equivalents | $12,139,591 | $12,139,591 | $5,391,305 |
| Short-term Investments | $24,331,524 | $24,331,524 | $16,153,890 |
| Total Current Assets | $52,563,803 | $52,563,803 | $39,797,358 |
| Total Current Liabilities | $6,647,177 | $6,647,177 | $4,898,366 |
| Operating Cash Flow (9mo) | N/A | $13,581,620 | $7,230,229 |
Liquidity: Total cash and short-term investments stood at $36,471,115 as of March 31, 1998. The Company maintains an unsecured line of credit of $750,000 with no borrowings.
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 9% for the quarter and 9% for the nine-month period compared to the prior year. R&D Systems sales grew 15% (quarter) and 16% (nine months), driven by cytokines, antibodies, and hematology products. R&D Europe sales declined 5% (quarter) and 6% (nine months) due to the discontinuance of the molecular biology product line, though continuing product lines grew 25%.
- Profitability: Net earnings rose 36% for the quarter and 41% for the nine-month period. Gross margins improved for the nine-month period (69.4% vs. 67.9%) despite a slight dip in the quarter (69.0% vs. 69.4%).
- Expenses: Selling, general, and administrative (SG&A) expenses decreased 9% in the quarter but increased 5% over nine months, largely due to occupancy and advertising costs at R&D Systems, offset by restructuring savings at R&D Europe. R&D expenses decreased 7% (quarter) and 12% (nine months) primarily due to reduced payments under a joint research agreement in Europe.
- Stock Activity: The Company executed a 2-for-1 stock split in November 1997. It repurchased 20,000 shares for $280,000 in the first nine months of fiscal 1998, compared to 234,600 shares for $2.98 million in the prior year.
Guidance, Outlook, and Risks
- Capital Expenditures: Planned capital additions for the remainder of fiscal 1998 are approximately $0.6 million, to be funded by available cash and operating flows.
- Strategic Investment: The Company is obligated to purchase an additional $3 million of preferred stock in ChemoCentryx, Inc. over the next two years upon achievement of milestones, potentially increasing ownership to 49%.
- Dividends: The Company has never paid cash dividends and has no plans to do so in fiscal 1998.
- Risks: Key risks include the acceptance of new biotechnology products, price competition in the cytokine market, retention of OEM customers, and the success of R&D efforts. The Company also notes the impact of exchange rates on European operations.
- Accounting Changes: The Company anticipates adopting SFAS No. 131 (Segment Reporting) and SFAS No. 130 (Comprehensive Income) effective July 1, 1998.
Investor Verification Checklist
- Verify the sustainability of the 15-16% sales growth in the R&D Systems division versus the decline in R&D Europe.
- Confirm the timeline and milestones for the additional $3 million investment in ChemoCentryx, Inc.
- Monitor the impact of the discontinued molecular biology product line on future European revenue stability.
- Review the Company's stock repurchase program status, noting the extension to purchase an additional $5 million of common stock.
- Assess the effectiveness of cost controls in R&D Europe following restructuring charges in the prior year.